Phase II study of anti-CD3 x anti-HER2/neu (HERBi) armed activated T cells (ATC) after neoadjuvant chemotherapy in patients with HER2/neu (0-2+)-negative stage II-III breast cancer

被引：0

作者：

Bumma, Naresh ^{[1
]}

Kin, Andrew ^{[1
]}

Abrams, Judith ^{[1
]}

Deol, Abhinav ^{[1
]}

Weise, Amy ^{[1
]}

Thakur, Archana ^{[2
]}

Lum, Lawrence ^{[2
]}

机构：

[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[2] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P207

引用

页数：1

共 50 条

[21] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
Tokuda, Y
Watanabe, T
Omuro, Y
Ando, M
Katsumata, N
Okumura, A
Ohta, M
Fujii, H
Sasaki, Y
Niwa, T
Tajima, T
BRITISH JOURNAL OF CANCER, 1999, 81 (08) : 1419 - 1425
[22] A phase II study of humanized anti-HER2 monoclonal antibody (rhuMAB HER2) and weekly chemotherapy in women with metastatic progressive breast cancer
Colozz, M
Gori, S
Mosconi, AM
Di Stefano, A
Mazzoni, F
Maestri, A
Cherubini, R
Crino, L
Tonato, M
ANNALS OF ONCOLOGY, 2000, 11 : 39 - 39
[23] Combining anti-CD3 activated T cells armed with anti-CD3 x anti-Her2 bispecific antibody may provide an additional anti-tumor effect after stem cell transplant for breast cancer.
Sen, M
Wankowski, DM
Lum, LG
EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 743 - 743
[24] Trafficking and clinical responses in SCID-beige mice bearing Her2/neu-positive tumors treated with Her2Bi-retargeted anti-CD3 activated T cells (ATC)
Davol, PA
Gall, J
Olson, S
Grabert, RC
Kouttab, NM
Lum, LG
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S18 - S19
[25] Phase I/II, open label, dose escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu (1+/SISH positive, 2+and 3+) expressing solid tumors progressing after standard therapy
Haense, N.
Jaeger, M.
Klunker, D.
Hozaeel, W.
Rafiyan, M. -R.
Sorgius, D.
Lindhofer, H.
Al-Batran, S. -E.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 106 - 106
[26] Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Kiewe, Philipp
Hasmueller, Stephan
Kahlert, Steffen
Heinrigs, Maja
Rack, Brigitte
Marme, Alexander
Korfel, Agnieszka
Jaeger, Michael
Lindhofer, Horst
Sommer, Harald
Thiel, Eckhard
Untch, Michael
CLINICAL CANCER RESEARCH, 2006, 12 (10) : 3085 - 3091
[27] Enhanced anti-breast cancer cyotoxicity, after autologous peripheral blood stem cell transplant (PBSCT) by boosting with multiple infusions of activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) prior to PBSCT
Lum, Lawrence G.
Al-Kadhimi, Zaid
Skuba, Cassara
Ratanatharathorn, Voravit
Uberti, Joseph P.
BLOOD, 2007, 110 (11) : 807A - 808A
[28] Enhanced HER2/neu specific T-cell immunity in vitro by HER2/neu Ii-key modified "agonist" class II peptides in breast cancer patients.
Murray, JL
Kawano, K
Efferson, C
Babiera, G
Meric-Bernstam, F
Ibrahim, N
Kallinteris, NL
Humphreys, RE
Von Hofe, E
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S198 - S198
[29] Infusions of T cells armed with anti-CD3 x anti-Her2/neu bispecific antibody modulate in vivo patient immune responses in phase I clinical trials for breast and hormone refractory prostate cancers.
Davol, PA
Gall, JM
Grabert, RC
Young, WB
Curnmings, FJ
Rathore, R
Colvin, GA
Elfenbein, GJ
Lum, LG
BLOOD, 2004, 104 (11) : 379A - 379A
[30] Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression
Khan, Qamar J.
O'Dea, Anne
Fabian, Carol J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua Matthew Varghise
Wagner, Jamie Lynn
Baccaray, Stella
Springer, Michelle
Yeh, Henry
Sharma, Priyanka
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →